SOPHiA GENETICS SA (NASDAQ:SOPH) Faces Financial Challenges Despite Revenue Growth

Core Insights - SOPHiA GENETICS SA is a key player in AI-driven precision medicine, focusing on enhancing healthcare outcomes through artificial intelligence [1] - The company reported financial challenges in its Q4 2025 earnings, with losses despite revenue growth [1] Financial Performance - For Q4 2025, SOPH reported an earnings per share (EPS) of -$0.28, missing the estimated EPS of -$0.25, indicating ongoing losses [2] - The company's revenue for the quarter was $21.7 million, exceeding the estimated $20.7 million, reflecting a 22% year-over-year increase [2] - SOPH's gross margin for Q4 2025 was 67.7% on a reported basis and 73.9% on an adjusted basis, showing scalability in its AI-native precision medicine platform [3] - The IFRS net loss for Q4 2025 increased by 27% to $19.2 million, while the adjusted EBITDA loss rose by 9% to $9.9 million [3][6] Annual Overview - For the full year 2025, SOPH achieved a revenue of $77.3 million, a 19% increase from the previous year [4] - The gross margin remained stable at 67.4% on a reported basis and improved to 74.2% on an adjusted basis [4] - The IFRS net loss for the year was $79 million, a 26% increase year-over-year, and the adjusted EBITDA loss was $41.5 million, up by 3% [4] Valuation Metrics - SOPH's price-to-sales ratio stands at about 3.99, indicating a high valuation relative to sales [5] - The enterprise value to sales ratio is approximately 3.74, reflecting the company's valuation relative to its sales [5] - The enterprise value to operating cash flow ratio is negative at around -7.15, indicating challenges in generating positive cash flow from operations [5] - Despite these challenges, SOPH maintains a strong current ratio of approximately 2.80, suggesting a solid ability to cover short-term liabilities with short-term assets [5]